IndraLab
Statements
reach
"Consistent with this view, global knockout of the cGAS-cGAMP-STING downstream target TBK1 or IRF3, or pharmacological inhibition of IkappaB kinase epsilon (IKKepsilon) and TBK1 by amlexanox, reduced body weight, enhanced insulin sensitivity, and improved glucose tolerance in obese mice and in a subset of patients with type 2 diabetes."
eidos
"Consistent with this view , global knockout of the cGAS-cGAMP-STING downstream target TBK1 ( 37 ) or IRF3 ( 38 ) , or pharmacological inhibition of IkappaB kinase epsilon ( IKKepsilon ) and TBK1 by amlexanox , reduced body weight , enhanced insulin sensitivity , and improved glucose tolerance in obese mice and in a subset of patients with type 2 diabetes ( 34,39 ) ."
reach
"Inhibition of TBK1/IKKε with two different small molecules, amlexanox (Fig. 8A and Fig. S4) or BX-795 (Fig. S4), also reduced poly(I:C)-induced Akt P-S473, demonstrating that TBK1/IKKε activity positively controls mTORC2 signaling to Akt in RAW264.7 macrophages.We next isolated primary bone marrow derived macrophages (BMDMs) from Mtor and Mtor mice."
reach
"Collectively, these studies show that IKBKE plays a pivotal role in human malignancy and could be a critical therapeutic target for PDAC.Recent studies have identified two small-molecule compounds, amlexanox and CYT387, which directly inhibit IKBKE/TBK1 kinase activity [10,18,19]."